117 results about "Isotype" patented technology

Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.

The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.

This invention discloses functional humanized antibody against CD20 molecules and its application. The functional humanized antibody specifies human CD20 molecules, and is composed of a light chain and a heavy chain, each of which comprises a constant region and a variable region. The constant region of the heavy chain is isotypic human IgG1 constant region, and that of the light chain is isotypic human kappa constant region. The variable region of the heavy chain is shown in SEQ ID No.2, and that of the light chain is shown in SEQ ID No.1. The functional humanized antibody has low immunogenicity. Experiments show that the functional humanized antibody has the same specificity and affinity as the original murine antibody. Drugs containing the functional humanized antibody and its derivatives can be used for treating cancers or immune system diseases with the high-expression of CD20, such as rheumatic arthritis and lupus erythematosus.

The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

The invention relates to a mammalian cell, particularly a human cell, expressing a first isoform of a surface protein, wherein the first isoform is functionally indistinguishable, but immunologicallydistinguishable from a second isoform, for use in a medical treatment of a patient having cells expressing the second isoform form of the surface protein. The invention further relates to an agent selected from 1) a compound comprising, or consisting of, an antibody or antibody-like molecule and 2) an immune effector cell bearing an antibody-like molecule or an immune effector cell bearing a chimeric antigen receptor, for use in a method of treatment of a medical condition, wherein the agent is specifically reactive to either a first or a second isoform of a surface protein, wherein the firstisoform is functionally indistinguishable, but immunologically distinguishable from the second isoform, and wherein the agent is administered to ablate a cell bearing the isoform that the agent is reactive to.

The present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies. The method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two-dimensional gel electrophoresis followed by Western Blot analysis. The identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies. The invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific beta-tubulin isoforms were detected in the sera of neuroblastoma patients.

Disclosed are mammalian nucleic acid sequences encoding α1I subunit isoforms of a voltage-gated calcium channel. Specifically disclosed are novel variants of the α1I subunit designated herein as α1I-1 and α1I-2. In other aspects, the disclosure relates to expression vectors which encode the novel subunits of the invention, as well as cells containing such vectors. Antibodies specific for each of the variant subunits are also provided. The nucleic acid sequences of the invention find application, for example, in screening for compounds which modulate the activity of voltage-gated calcium channels and also in diagnostic methods for diagnosing various T-type channel mediated disorders, e.g., epilepsy, cancer, pain, sleep disorders and the autoimmune disease Lambert-Eaton Syndrome. Diagnosing defects in α1I subunit genes of a patient with a neuronal disease such as epilepsy are also included. An additional application of the nucleic acid sequences of the invention is in therapeutic methods of treatment for α1I subunit mediated disorders.

The invention discloses a long non-coding RNA (lncRNA) marker derived from adipocyte exosomes and application and product of the lncRNA marker. The lncRNA marker is a long non-coding RNA TUG1 gene orhomolog, mutant or isotype thereof; the lncRNA TUG1 is derived from exosomes secreted by breast cancer cells, tumor interstitial adipocytes or tumor interstitial fibroblasts, or body fluid exosomes; and the lncRNA TUG1 is highly expressed in mast adipocytes and breast cancer, and can be delivered to breast cancer cells from the adipocytes through the exosomes. The lncRNA marker derived from the adipocyte exosomes is a product for detecting the long non-coding RNA TUG1 of the tumor interstitial adipocytes and the long non-coding RNA TUG1 of tumor, and lays the foundation for early diagnosis ofthe breast cancer; and as a therapeutic target, and as an indicator of disease treatment, the long non-coding RNA TUG1 is applied clinically, and thus, a theoretical basis is provided for prevention and mechanism research of the breast cancer.

The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient.

The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

The invention relates to the technical field of medical diagnosis, and specifically relates to an X-linked lymphoproliferative syndrome diagnostic kit and application thereof. The kit comprises anti-human CD 3, CD56, CD8a and SAP flow fluorescent antibodies, an isotype control fluorescent antibody of the anti-human SAP flow fluorescent antibody, an anti-human SAP Western Blot antibody, and a secondary antibody corresponding to the anti-human SAP Western Blot antibody. A method for detecting SAP protein abundance in CTL and NK cells based on the diagnostic kit is quick to detect, high in flux, high in accuracy, and small in human factor influence.